Atopic Dermatitis: Updated Guidelines From the AAAAI/ACAAI Joint Task Force on Practice Parameters

American Family Physician. 2024;110(4):437-439.

Author disclosure: No relevant financial relationships.

This clinical content conforms to AAFP criteria for CME.

KEY POINTS FOR PRACTICE

• Treatment of atopic dermatitis with a midpotency topical corticosteroid once daily or a topical calcineurin inhibitor two to three times per week is safer and more effective for maintenance of remission than episodic treatment of flare-ups.

• Dilute bleach baths are beneficial for moderate to severe cases of atopic dermatitis.

• Systemic corticosteroids, elimination diets, and topical antimicrobial agents should be avoided in patients with atopic dermatitis .

From the AFP Editors

The American Academy of Allergy, Asthma and Immunology (AAAAI)/American College of Allergy, Asthma and Immunology (ACAAI) Joint Task Force on Practice Parameters updated guidelines for managing atopic dermatitis (eczema). Table 1 summarizes recommendations relevant to family physicians.

TABLE 1. Atopic Dermatitis Treatment—AAAAI/ACAAI Guideline Recommendations

Treatment Recommendation Strength Certainty
Topicals Cases of any severity    
Use over-the-counter moisturizers rather than prescription moisturizers Conditional Low
Add a topical corticosteroid Strong High
Add a topical calcineurin inhibitor Strong High
If using mid- to high-potency topical treatment, apply once daily Conditional Moderate
Use maintenance therapy with a low- to midpotency topical corticosteroid or topical calcineurin inhibitor Strong Moderate
Avoid topical antimicrobials in patients with no clear signs of infection Conditional Very low
Mild to moderate cases    
Add crisaborole 2% ointment (available as brand Eucrisa) Conditional Moderate
Dilute bleach baths Moderate to severe cases    
Use dilute bleach baths Conditional Low
Mild cases    
Avoid bleach baths Conditional Low
Elimination diets Cases of any severity    
Avoid elimination diets Conditional Low

Note: The full guideline for conditions for all recommendations, practical issues, implementation considerations, summary handouts, and additional information is available: https://www.annallergy.org/article/S1081-1206(23)01455-2/fulltext.

AAAAI/ACAAI = American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology.

Adapted with permission from Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine–based recommendations. Ann Allergy Asthma Immunol. 2024 ;132(3):277.

Winfred Frazier, MD, MPH

University of Pittsburgh Department of Family Medicine, Pittsburgh, Pa.

Lynda Schneider, MD

Boston Children's Hospital, Boston, Mass.

Derek K. Chu, MD, PhD

McMaster University, Hamilton, Ontario, Canada

Author disclosure: No relevant financial relationships.

Coverage of guidelines from other organizations does not imply endorsement by AFP or the AAFP.

This series is coordinated by Michael J. Arnold, MD, MHPE, AFP Assistant Medical Editor.

A collection of Practice Guidelines published in AFP is available at https://www.aafp.org/afp/practguide.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.